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Abstract
Parasitic diseases present a considerable socio-economic impact to society. Zoonotic parasites can 
result in a considerable burden of disease in humans and substantive economic losses to livestock 
populations. Ameliorating the effects of these diseases may consist of attempts at eradicating specific 
diseases at a global level, eliminating them at a national or local level or controlling the disease to 
minimise incidence. Alternatively with some parasitic zoonoses it may only be possible to treat human 
and animal cases as they arise. The choice of approach will be determined by the potential effectiveness
of a disease control programme, its cost and the cost effectiveness or cost benefit of undertaking the 
intervention. Furthermore human disease burden is being increasingly measured by egalitarian non-
financial measures which do not sit comfortably with measurements of economic costs in livestock. 
This adds additional challenges to assessing socio-economic burdens of zoonotic diseases. Using 
examples from the group of neglected zoonotic diseases, information regarding the socio-economic 
effects of these diseases are reviewed and the use of this information in decision making with regard to 
control and treatment of these diseases is discussed.
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1. Introduction
One Health is dedicated to improving the lives of all species—human and animal—through the 
integration of human medicine, veterinary medicine and environmental science. The concept of ‘‘One 
Health’’ has evolved from ‘‘One Medicine,’’ an idea which originated from the veterinary 
epidemiologist Calvin Schwabe in the 1960s to demonstrate that there are no major conceptual 
differences between human and veterinary medicine, and that integrated work should be promoted 
(Schwabe, 1984) In 2005 it was estimated that of 1407 species of recognised human pathogens, 58% 
were zoonotic (Woolhouse and Gowtage-Sequeria, 2005) illustrating the need for a one health approach
to many human and animal diseases.   Many upper income countries have controlled or eliminated a 
number of animal and zoonotic diseases through expensive intervention programmes. Different disease 
priorities and resource availability exist in low income countries, whilst in high income countries 
increased livestock intensification and public health interventions may render some continuing 
programmes redundant.
As veterinary parasitologists, we are interested in parasitic diseases that impact on animal health
and in parasitic zoonoses. However, we live in a world of limited resources and  therefore it is 
important to prioritize resources to limit the impact of these diseases.  In this article I would like to 
summarize how a number of tools can be used to define the socio economic burden of diseases on 
society, and how this evidence can be used to develop disease control priorities illustrated with 
reference to a number of neglected zoonoses and “non-neglected” zoonoses
For a number of zoonoses the state has assumed responsibility for intervention to decrease  
disease  incidence. This may be a control or elimination programme although never an eradication 
programme as the latter term is widely misused. “Control” is defined as the reduction of disease 
incidence, prevalence, morbidity, or mortality to an acceptable level, as determined by the country or 
area in question. “Elimination” is defined as the reduction of disease incidence to zero in a defined 
geographic area. Once elimination has been achieved it requires ongoing public health measures to 
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prevent disease re-emergence “Eradication” is defined as the reduction of disease incidence  globally to
zero (Dowdle, 1998). The distinction is important. For example despite the claim that Echinococcus 
granulosus appears to have been “eradicated” from New Zealand (Davidson, 2002), it has actually been
eliminated as on-going measures are required to maintain the country free from the parasite. If global 
eradication had been achieved then these measures would no longer be necessary. Rhinderpest, which 
for millennia was considered to be the animal disease with the greatest impact on human well-being, 
has been eradicated (Mariner et al., 2012). Hence no further measures to control this disease are 
required anywhere.
The control or elimination, at least on a nationwide basis, of zoonotic diseases are laudable 
aims, but we should remain critical of such programmes, which are often expensive and can cause 
major bystander effects to livestock producers that may be worse that the original problem. If the aim is
the protection of public health, programmes should be evaluated not only to ensure they are doing so, 
but also to ensure they are doing so in a cost effective manner. They should also remain competitive 
relative to other forms of public health intervention such as investing in the control of other diseases or 
indeed building hospitals. With zoonoses there is also the additional major benefit of reducing animal 
health losses which should be factored into the analysis. This may result in a disease having a higher 
priority then purely its impact on human health. The dual socio-economic costs to human health and 
the livestock industries can also lead to challenges in calculating the impact of these diseases on 
societies as human disease burden and animal disease costs may be measured by very different and 
incompatible methodologies (Carabin et al., 2005).
2. Socio-economic burden of a disease.
This can broadly be defined as the impact a disease has on society measured by financial cost, 
mortality, morbidity or other indicators. To be able to assess the impact of any disease we need to be 
able to measure it. With parasitic diseases that have an impact on agricultural animals the financial 
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impact of these diseases is the most important metric. However in resource poor countries animal 
disease will also have an indirect impact on human health through financial hardship or malnutrition. 
Livestock have many values to society including direct production of food, their use in agricultural 
production (such as draft power or sources of manure), as a deposit of wealth, and valuable cultural 
benefits. Loss of livestock through disease can impact in these areas. In high income countries 
livestock are mainly treated as a financial asset and one of many sources of food. In low income 
countries animals have a range of functions. When livestock losses occur due to disease the direct costs
can be estimated using market prices. Indirect costs are more difficult to estimate, but may be more 
important than the direct financial costs.
To estimate the societal burden of zoonoses, methods are needed to combine the adverse effects 
on society of disease and reduced productivity in livestock with those of disease and lower levels of 
well-being and productivity in people. Direct costs to human health include the costs of death, sickness 
and injury and the costs of treating the disease. Indirect costs include the loss of wages to workers who 
are sick and the reduced productivity of workers who may have sub-clinical effects of disease. The 
various methods for measuring the cost or impact of parasitic zoonoses are discussed extensively by 
Carabin et al. (2005). 
2.1. Disability adjusted life years
This is a measure of human population health that combines mortality and morbidity into one 
unit to measure the impact of a disease on society. It is a composite measure and can be written as
DALY = YLL + YLD
Where YLL is the years of life lost due to premature mortality. This can be calculated from the the life 
expectancy at the age of death which  is generally drawn from the Coale-Demeny Model Life Table 
West which can be downloaded from the WHO website  
(http://www.who.int/entity/healthinfo/bodreferencestandardlifetable.xls).   The YLD is the years of life 
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lived with a disability and is the number of health years of life lost weighted by the severity of the 
condition. Simple examples can be used to demonstrate how a DALY is calculated. A healthy male of 
age 50 years would have a life expectancy of an additional 31 years. Thus if he were to suffer sudden 
death resulting from anaphylaxis due to a ruptured hydatid cyst he would loose 31 years of healthy life 
or 31 YLLs. Since death was sudden there is no time lived with a disability and hence the total numbers
of DALYs lost is 31. On the other hand if he was infected with neurocysticercosis resulting in epilepsy 
and this epilepsy remained untreated, he might still be expected to live 31 years. Untreated epilepsy has
a mean disability weight of 0.15 (Murray, 1996) and hence the numbers of YLLs lost is zero, but he 
loses 0.15*31 YLDs or 4.65 YLDs or a total of 4.65 DALYs. The disability weight varies with the 
function of the patient and can be estimated by a variety of techniques, including a time trade off such 
as undertaking a study over a population of individuals and asking them how many years they would 
trade at a certain level of disability to be in complete health (Schwarzinger et al., 2003) . Thus an 
average 50 year old male with epilepsy of average severity would be prepared to trade 4.65 years of 
healthy life (or 15% of his remaining life expectancy) to be “cured” of epilepsy. At a population level 
the numbers of DALYs lost to echinococcosis or cysticercosis would be estimated from the incidence 
of fatalities in each age group and gender to calculate the YLLs and similarly the incidence and 
duration of sequelae and their disability weights for non-fatal outcomes. 
The effectiveness of intervention strategies can be calculated as the number of DALYs 
estimated to occur due to a given condition in the absence of intervention minus the number of DALYs 
expected if control measures were implemented. However, this disregards any additional benefits of 
disease control to agriculture (e.g. anthelmintic treatment of dogs reduces cystic echinococcosis 
incidence in both humans and sheep). Nevertheless, if a total societal financial analysis is undertaken, 
the true cost-effectiveness of control, in terms of DALYs saved, can be estimated by implementation of 
cost sharing between sectors proportional to each sector’s overall benefit (Roth et al., 2003). 
100
105
110
115
120
3. Neglected parasitic zoonoses
There are a number of neglected parasitic zoonoses. At an initial meeting on neglected zoonoses at 
WHO in 2005 a list of 7 neglected zoonoses were agreed (WHO, 2006). These were echinococcosis, 
rabies, brucellosis, bovine tuberculosis, zoonotic trypansomosis, cysticercosis and anthrax. By 2010, a 
further two parasitic zoonoses had been added to the list, namely fasciolosis and  leishmaniosis. 
Furthermore fish born trematodes, zoonotic schistosmiosis (Schistosoma japonicum) and toxoplasmosis
were also suggested (WHO, 2011). These are, for the most part, diseases which have been present for 
centuries and which are usually associated with populations living in close proximity to their animals. 
These endemic zoonoses fall very much into the category of neglected diseases and as a result some are
now re-emerging health problems. They affect the poorest communities. Because they also affect 
livestock, causing lowered productivity or death, they not only attack peoples' health, but also their 
livelihoods. Using these as examples we can see how studies on the socio-economic burden of disease 
can be used to develop priorities for the control.
3.1. Cystic Echinococcosis
The burden of cystic echinococcosis (CE) caused by Echinococcus granulosus, both in terms of 
monetary burden and/or DALYs has been estimated globally as in a number of countries ( Torgerson et 
al., 2000, 2001, 2008, 2010; Torgerson and Dowling, 2001, Budke et al., 2004, 2006, Majorowski et al.,
2005, Benner et al., 2010;Fasihi Harandi et al., 2012). The global burden of CE is over 1 million 
DALYs with a financial burden in excess of $1 billion per annum (Budke et al., 2006). In many areas 
the local burden of cystic echinococcosis is substantial; in some rural nomadic pastoralist communities 
such as in western China, echinococcosis may be one of the highest single causes of disease burden 
within the population (Budke et al., 2004). It has been shown that given certain circumstances, CE can 
be completely eliminated by aggressive and regular treatment of dogs with a cestocidal anthelmintic 
such as praziquantel, combined with dog control measures and  veterinary supervion of the slaughter of
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livestock and other animals serving as intermediate host. Factors that facilitate complete elimination 
include the lack of a wildlife host and geographical isolation. This has resulted in successful 
programmes in New Zealand, Iceland, Tasmania, Cyprus and the Falkland islands (reviewed by Craig 
and Larrieu (2006) The same principles can be used in countries where there may be encroachment 
from non-control areas in neighbouring districts. Cost benefit studies of possible control programmes in
highly endemic areas such as China suggest that the financial return appears to be greater than the cost 
of implementation even if the local epidemiology does not allow total elimination. Likewise the cost 
per DALY averted is in the order of just $10-$12 (Budke et al., 2005) making it highly cost effective. 
However these calculations were made in a region which has amongst the highest prevalences of 
human echinococcosis, with certain Tibetan communities having a prevalence of 5-10% or more 
(Budke et al., 2004). Similar studies would also be needed lower to confirm this in communities where 
the human burden is lower. CE should receive high priority as it has both a high global and local 
disease burden with economic costs in animals. There are also cost effective tools for control and 
elimination (Table 1). However, one place where elimination is not possible and control a challenge is 
in Australia because of the establishment of the cycle between dingoes and marsupials, both of which 
seem to be highly susceptible to infection (Jenkins, 2006).
3.2. Alveolar echinococcosis
Alveolar echinococcosis (AE) is confined to the northern hemisphere. In some communities in 
China the disease has a very high local burden (Budke et al., 2004). In Europe and central Asia the 
disease appears to be emerging in some localities (Schweiger et al., 2007, Nahorski et al 2013; 
Ussymbaeva et al., 2013 ). The global burden of disease has been estimated at about 666,000 DALYs 
per year (Torgerson et al., 2010) and thus the impact is high – mainly due to the high mortality rate as 
the number of new cases per year is approximately 18,000. Over 90% of the burden is in China. In 
Switzerland there are between 20 and 30 new cases per year, resulting in an annual burden of 
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approximately 77 DALYs (Torgerson et al., 2008). Because of the wildlife reservoir, and the cycle 
involving foxes and small mammals, control is a challenge and elimination is probably not possible 
with present technology. There is a major concern in Europe of increased risk of human infection 
resulting from the increased numbers of urban foxes (Deplazes et al., 2003; Schweiger et al., 2007). 
This has stimulated pilot control programmes to treat foxes and it has been shown that distributing fox 
baits containing praziquantel on a regular basis can substantially reduce the prevalence of E. 
multilocularis in foxes (Hegglin and Deplazes, 2008). The question remains as to the cost effectiveness 
of this intervention as it is still uncertain to what extent the human incidence is likely to decrease from 
such a programme. Treatment of cases as they arise is effective in high income countries with advanced
health care, such as Switzerland and France (Torgerson et al., 2008; Piarroux et al., 2011;). Such 
treatment in Switzerland costs about €6000 per DALY saved, which although expensive is cost 
effective in terms of the high GDP per head in Switzerland (Torgerson et al., 2008). In China, in 
regions where the human incidence is very high, dogs are likely to play a role in transmitting E. 
multilocularis to humans. Modelling studies have suggested that regular treatment of dogs with 
praziquantel in such endemic communities will result in the decrease in incidence of human AE. 
However, this could be as little as 50% reduction if the dog is acting as a conduit from the wild life 
cycle as treating dogs will not affect the biomass in the fox and rodent population. In contrast, if dogs 
are reinfecting small mammals in an anthropomorphic cycle, then regular treatment of dogs could 
reduce human AE by 90% or more (Budke et al., 2005) . Both scenarios are cost effective in reducing 
human disease in terms of $ per DALY averted.  
3.3 Cysticercosis
Human neurocysticercosis is highly endemic in many low and middle income countries where there is 
widespread pork consumption. It has been largely eliminated from high income countries through 
slaughter control. Of those diseases on the list of neglected zoonoses, it alone has the potential to be 
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eradicated globally as the parasite life cycle specifically requires pigs and humans with no other hosts 
involved in transmission. The global burden of human cysticercosis is likely to be high. In a systematic 
review of 12 studies from Latin America, Sub-Saharan Africa and South-east Asia it has been 
estimated that 29.6% of individuals with epilepsy have neurocysticercosis (Ndimubanzi et al., 2010). In
the context that the burden of epilepsy in low and middle income pork consuming countries is 
approximately 6.8 million DALYs per annum, this indicates the very large burden due to Taenia solium
cysticercosis globally (Torgerson and Macpherson, 2011). Several local studies have also indicated that
this zoonosis has a substantial impact on endemic communities. In the Eastern Cape of South Africa, 
the annual monetary burden of cysticercosis has been estimated at between US $ 18.6 million and US $
34.2 million (Carabin et al., 2006). In Mexico is has been estimated that neurocysticercosis results in 
0.25 DALYs per 1000 person years (Bhattarai et al., 2012). With a population of 114 million this 
represents about 28,500 DALYs per year due to neurocysticercosis. A study in the West of Cameroon 
suggested that the burden of neurocysticercosis was 9 per 1000 person years (Praet et al., 2009). 
However this may be an over estimate as it is somewhat higher than the estimate for the burden of 
epilepsy (2.45 DALYs per 1000 person years ) in the Cameroon (Bhattarai et al., 2012). 
There are few documented formal programmes to control cysticercosis. In Henan province, 
China, it has been reported that mass anthelmintic treatment of humans reduced the prevalence of 
human taeniosis from 0.65% (16,159/2,480,419) in 1978 to 0.06% (8,583/13,901,265) in 1983, with a 
corresponding decrease in the annual incidence of human cysticercosis from 31.4 cases per million to 
1.3 cases per million (Wu et al., 2012). Elsewhere mass treatment with praziquantel or nicloseamide 
has been demonstrated to be successful on a local scale (Flisser et al., 2011). Taenia solium has also 
been included in a priority list of six human diseases (polio, mumps, rubella, dracunculiasis, lymphatic 
filariasis and cysticercosis) targeted for global eradication (WHO, 2006). Therefore T. solium should 
receive the highest priority due to its high global burden and economic costs and the potential for 
eradication.
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3.4 Human African Zoonotic Trypanosomiosis
Human African zoonotic trypanosomiosis is caused by Trypanosoma brucei rhodesiense with 
reservoirs in both domestic and wild species (Fevre et al., 2008a). Human African trypanosomiosis 
(HAT) has a burden of over 1.3 million DALYs, but perhaps less than 10% is due to the zoonotic T.b. 
rhodeiense. In Uganda, from a perspective of hospital based interventions alone, it costs approximately 
US$8.50 per  DALY averted for chemotherapy, nursing and associated costs of infected people (Fevre 
et al., 2008b). Case finding by screening in and around known foci of the disease is thus highly cost 
effective. Of great importance with zoonotic HAT, however, is the extension of the area of endemicity, 
with parts of Uganda being at substantial risk of becoming co endemic with T. b. rhodensiense and T. b.
gambiense which would greatly complicate efforts to control and treat this disease. Consequently, to 
prevent this scenario, a mass treatment programme of cattle with trypanocidal drugs was initiated in 
northern Uganda (Kabasa, 2007). This can also be combined with insecticides in both cattle and pigs to 
reduce levels of the tsetse fly vector.
Other programmes have included mass treatment of pigs, cattle and other potential reservoir 
hosts, which is beneficial to animal health and productivity. The lower incidence in animals reduces the
costs of human trypanosomiosis as there are fewer patients to treat (Magona and Walubengo, 2011). 
Thus both human surveillance and treatment, and mass treatment of reservoir hosts are cost effective 
for the control of zoonotic HAT. So although in a global perspective the human burden of HAT is 
modest, locally it can be high, especially since there may be widespread under-diagnosis of HAT. For 
example, febrile illnesses in many parts of Africa are often assumed to be malaria, resulting in cases of 
sleeping sickness going undiagnosed and receiving inappropriate treatment (WHO, 2011). In addition, 
there may be high economic costs to livestock and tools are available to ameliorate transmission, 
although there are few data on the cost effectiveness of such tools. Appropriate treatment of human 
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cases is highly cost effective.
3.5. Food borne trematodes
A number of foodborne trematodes present a substantial burden for human health globally. Clinically 
important trematode infections in humans include Clonorchis sinensis, Opisthorchis viverrini, Fasciola
spp, Paragonimus spp and intestinal flukes (Sripa et al., 2010). It has been estimated that over 750 
million people are at risk of infection with foodborne trematodes, with approximately 56 million 
infected at any one time. Of these, 7.9 million suffer severe sequelae and there are over 7000 deaths per
year. This results in a global burden of 665,000 DALYs per annum (Fürst et al., 2012a).  
3.5.1. Fasciolosis
Fasciolosis, caused by Fasciola hepatica or F. gigantica, has a widespread geographical range with a 
huge impact on livestock. However human fasciolosis tends to be more focal and is related to the 
consumption of certain plants that are contaminated with metacercariae. It is estimated that there are 
approximately 2.65 million cases of human fasciolosis globally. Of these 2.50 million (94%) are from 
either the Middle East (Egypt and Iran) or Latin America (Bolivia, Ecuador and Peru). The global 
burden of human disease is estimated to be 35,000 DALYs annually (Fürst et al. 2012a). Because of the
rather low health impact to humans, control of fasciolosis is unlikely to be a cost-effective public health
programme other than in a few communities which have high levels of endemicity (eg the Nile Delta). 
However, fasciolosis is known to have a huge impact on livestock production. In Switzerland, with an 
estimated prevalence in cattle of between 15 and 20% ( Rapsch et al., 2006), the disease has an annual 
impact of approximately €52 million per annum or €255 per infected animal (Schweizer et al., 2005). 
Reliable estimates for the global financial losses caused by Fasciola spp to the livestock industry are 
not available. However, Copeman and Copland (2008) estimated that in southern and eastern Asia 
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estimated that between 51 and 118 million cattle or buffalo are infected with F. gigantica, resulting in 
annual economic losses of AU$4 billion and AU$11 billion per annum. This represents between 11 and
26% of large ruminants infected (over 452 million large ruminants). Therefore it can clearly be seen 
that the socio-economic burden of fasciolosis is mainly a livestock problem. However, effective control
of the parasitic infection in livestock will avoid large livestock losses and will help to reduce the burden
of human disease in some localities.  
3.5.2. Clonorchiosis and Opisthorchiosis
Clonorchis sinensis and Opisthorchis viverrini can induce cholelithiasis, cholestasis, cholangitis, 
cholecystitis, biliary and liver abscess and cirrhosis, pancreatitis, hepatitis, and cholangiocarcinoma. 
Because of the potentially more severe sequelae including fatal carcinomas, these parasites represent a 
much greater burden to the human population that fasciolosis. It has been estimated that nearly 24 
million people are infected globally with nearly 7000 deaths annually resulting in 350,000 DALYs 
annually (Fürst et al., 2012a). These are fish-borne zoonoses and control is largely through ensuring 
fish is well cooked prior to consumption improvement of sanitation to prevent parasite eggs reaching 
fish habitats, and education (Fürst et al., 2012b) In farmed fish snail control and reducing 
contamination of ponds by eggs from infected definitive hosts has beneficial effects (Clausen et al., 
2012). Praziquantel is the treatment of choice for infected humans (Fürst et al., 2012b), but there 
appears to be little evidence with regard to the cost effectiveness or cost benefit of any intervention 
strategies.
3.5.3.Paragonimosis and intestinal flukes
There are an estimated 23 million people globally infected with Paragonimus resulting in about 250 
deaths annually at the cost of nearly 200,000 DALYs. (Fürst et al., 2012a). Intestinal flukes infect just 
under 7 million people resulting in an annual loss of approximately 84,000 DALYs. Intervention is 
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similar to the control of chlonorchiosis  including measures to prevent
infection in the freshwater crustaceans from which people acquire Paragonimus spp., and of
fish and water plants, which are the sources of human infections with Metagoniumus
yokogawai and Fasciolopsis buski, respectively..
3.5. Zoonotic schistosomiosis
Most zoonotic cases of schistosomosis are due to S. japonicum. New disability weights given to S. 
japonicum (Finkelstein et al., 2008) and updated information on global prevalence (Van der Werf et al., 
2003) indicate that the true burden of human schistosomosis is substantially higher than previously 
thought and is currently estimated to be approximately 70 million DALYs annually (King and 
Dangerfield-Cha, 2008; Hotez and Fenwick, 2009;). If zoonotic schistosomosis is responsible for only 
a small proportion of this global burden, then it would still mean that this disease has one of the highest
global burden of any parasitic zoonosis. S. japonicum currently is an important zoonosis in five 
provinces in China, where more than 50 million people are at risk and approximately one million 
people and several hundred thousand livestock are infected (McManus et al., 2010) . S. japonicum also 
occurs in 28 provinces in the Philippines and in discrete foci in the province of Central Sulawesi in 
Indonesia (King, 2009). Economic losses for infections in livestock have been seldom studied and 
hence are less defined, but add significantly to the economic burden and suffering of communities. It is 
known that the non-zoonotic S. bovis can result in substantial economic losses in livestock (Hunt 
McCauley et al., 1984) and hence, by analogy, direct production losses due to S. japonicum are likely.
S. japonicum was successfully eliminated from Japan through snail control and socio-economic 
changes. The national schistosomosis control program in China is recognized as one of the most 
successful globally: the cornerstone of the programme is mass chemotherapy. S. japonicum is regarded 
by the Chinese authorities as being on par with HIV/AIDS, TB and hepatitis B as a public health 
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problem (Wang et al., 2008). Integrated control will incorporate the use of human and bovine 
chemotherapy, health education/promotion, improved sanitation and focal use of molluscicides (Wang 
et al., 2009). Control and elimination of zoonotic Schistosoma species provides a serious challenge but 
successes already achieved show that it can be done.
3.6. Leishmaniosis
The most recent estimate of the global burden of leishmaniosis is approximately 2 million DALYs per 
annum (Lopez et al., 2006) of which a substantial but unknown proportion is of zoonotic origin.
There are challenges in reducing this burden through control or prevention. Altering the habitat of the 
vectors and mammalian reservoir hosts to reduce transmission to people, would require extensive and 
expensive environmental management and would be difficult to implement and sustain. However new 
tools have been developed for the control of canine leishmaniosis, such as insecticide-impregnated 
collars and topical insecticides which should be integrated with stray dog control. No cost-effective or 
cost-benefits studies have been undertaken on such programmes to ameliorate human leishmaniosis. 
Treatment of visceral leishmaniosis cases, such as in a relief programme, is highly cost effective and 
has been estimated at just US$ 18.40 for each DALY averted (Greikspoor et al., 1999); any intervention
that costs less than $25 per DALY averted is considered very good value for money by the World Bank.
3.7. Toxoplasmosis
Toxoplasmosis is a global zoonosis and a rare example of a parasitic disease that still causes a 
high human health burden in high income countries. Congenital toxoplasmosis is an important 
syndrome that may affect an infant born to a mother exposed to Toxoplasma for the fist time during 
pregnancy. Congenital toxoplasmosis can result in a number of syndromes ranging from chorioretinitis 
to hydrocephalus and neurological deficits (Jones et al., 2001). Because congenital toxoplasmosis can 
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result in foetal and neonatal death this leads to high numbers of years of life lost. This, combined with 
sequelae that may be severe and life long, also leads to high numbers of YLDs and hence a high burden
in terms of DALYs. In the Netherlands congenital toxoplasmosis  results in approximately 2300 
DALYs lost per year (Kortbeek et al., 2009). In addition, toxoplasmosis is a well known complication 
of HIV infection and acquired toxoplasmosis can cause chorioretinitis and is being increasingly linked 
to neurological and psychological disorders such as epilepsy, migraine and schizophrenia (Palmer, 
2007; Koseoglu et al., 2009; Torrey et al., 2012). A substantial proportion of human toxoplasmosis is 
food-borne and one estimate from the Netherlands suggests it is amongst the most important food-
borne diseases in terms of burden of disease (Havelaar et al., 2012). Toxoplasmosis generally appears 
to have a higher seroprevalence in low income countries and for this reason is likely to have a higher 
disease burden in such countries. In addition, there appears to be more pathogenic genotypes 
circulating in Latin America with greater severity of sequelae (Gilbert et al., 2008). Presently, there is 
little that can be done in terms of control or elimination of this disease although seroprevalences are 
decreasing in many parts of the world (Pappas et al., 2009), possibly linked with increased living 
standards. In addition, with increased intensification of the pork industry there is a lower prevalence in 
pork, with a lower risk of transmission to humans (Davies, 2011). At least in theory, transmission could
be ameliorated by testing meat for toxoplasmosis and ensuring infected meat is frozen to destroy the 
bradyzoites prior to consumption (Kijlstra and Jongert, 2009). In addition, the disease burden could be 
lowered by modifying behaviour in high risk groups such as pregnant women or HIV positive subjects 
to lower or prevent transmission to these groups. 
Toxoplasmosis can also cause significant livestock losses, particularly to the sheep industry. 
Infection of sheep with Toxoplasma gondii can result in early embryonic death and resorption, foetal 
death and mummification, abortion, stillbirth, and neonatal death. Severity of infection is associated 
with the stage of pregnancy at which the ewe becomes infected, the earlier in gestation, the more severe
the consequences (Dubey, 2009). The magnitude of the economic damage this parasite causes to the 
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sheep industry is not known, but one study in Uruguay in 1997 suggested that Toxoplasma-induced 
abortions resulted in losses amounting to between US$ 1.4 million and US$ 4.7 million per annum 
(Freyre et al., 1997). A commercial vaccine became available 20 years ago (Buxton and Innes, 1995) 
and can be used to reduce toxoplasmosis induced abortions in sheep flocks.
4. “Underneglected” zoonoses
There are a number of zoonotic diseases that are of low socio-economic significance, but 
continue to attract substantial investment due to reasons of trade in animal products, political reasons or
in a misunderstanding of their true impact on society. Alternatively, changes in technology or animal 
husbandry have resulted in eliminating animal to human transmission which was previously common, 
but policies for surveillance and control have not been amended to match the the now low or negligible 
public health risk. It can be argued that resources invested in the control of these zoonoses would 
produce a better return by investing in others that have a more substantive socio-economic impact.
4.1. Taenia saginata
T. saginata is completely dependent on humans for its transmission. However, unlike T. solium, the 
clinical effects of T. saginata are relatively trivial; usually at most limited to mild gastrointestinal signs 
and anal pruritis. With no fatalities and a very low disability weight, the global burden of disease due to
T. saginata is vanishingly low, despite it being a common parasitic infection in some low-income 
countries. The direct economic costs in terms of human disease are consequently also very low and 
limited to the cost of treatment. In cattle there are limited studies on the economic costs of infection on 
production losses. However, in most high-income countries inspection of beef for the presence of 
bovine cysticercosis is compulsory. Carcasses shown to be infected may be condemned, or downgraded
and refrigerated (Dorny and Praet, 2007). It is this downgrading that can cause substantive economic 
losses. Consequently, it can be argued that such programmes rather than the parasitic infection itself 
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which are causing the economic losses. Furthermore, current routine meat inspection has a very low 
sensitivity (Geysen et al., 2007). Therefore most infected beef enters the human food chain regardless.  
Because of the very low burden of human disease, interventions in the food chain such as meat 
inspection prevent the loss of very few DALYs. However the cost of treatment is very low, so cost 
effectiveness of treatment of individual human cases remains reasonable.
4.2. Trichinella spp.
Historically, meat controls for Trichinella spp. have been undertaken routinely in high-income 
countries and human trichinellosis was and is usually regarded as a severe human disease. However, 
human trichinellosis appears to have a surprisingly low burden of disease, even in endemic countries 
with no routine meat controls. A systematic review by Murrell and Pozio (2011) suggested that the 
numbers of reported cases globally were very low with just  65,818 cases and 42 deaths reported from 
41 countries between 1986 and 2009. Although likely to be an underestimate of the global incidence it 
still indicates that human disease is a rare event. However, in high income countries there is a large 
financial investment in the control of Trichinella spp. Due to regulations in the European Union (EU) 
there is compulsory inspection of most pig carcasses, with estimates of as much as  US$570 million 
spent annually by the EU for inspection of pork (Pozio, 1998). However, this is likely to be an 
exaggeration as the cost estimate for inspection by pooled sample digestion is 0.15€ per pig (Kapel, 
2005) and with 167 million pigs slaughtered per year, this would mean that costs could be in the region 
of €25 million per annum. The majority of EU countries (16 of 25 reporting data from slaughtered pigs;
Alban et al., 2011) are failing to find even a single infected pig. Nearly all of the 1179 positive pigs 
found in 2010 were from Romania .Thus the programme as it now stands prevents very little human 
trichinellosis in the EU. This low risk of human Trichinella infection is likely to be due to changes in 
husbandry with modern intensive pig farms being at very low risk with trichinellosis. It has to be noted 
that in the 19th century in Germany human trichinellosis was a significant problem with 12500 cases 
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reported between 1861 and 1890 (Hinz, 1991) but clearly the factors that promoted transmission of 
Trichinella to pigs are no longer present making the present programme redundant. Similarly in the 
USA, where most pork is intensively produced with very low risk of Trichinella infection, there are 
also very few cases of human trichinellosis (Davies, 2011). Thus, although we have tools to ameliorate 
transmission to humans these have low cost effectiveness when pork is intensively produced (Table 1)
4.3. Bovine tuberculosis
Although not a parasitic disease, many of the principals with regard to cost effectiveness and 
societal benefit apply to this disease in particular because in high income countries attempts at control 
are expensive and some proposed methods highly controversial. Bovine tuberculosis is potentially a 
serious zoonosis and in the past has caused widespread human disease and fatalities in high income 
countries, and exerts an unknown burden on low income countries. However, the evidence from past 
case series and the evolving epidemic of bovine tuberculosis in the UK suggests that it is a primarily 
food-borne disease, with transmission from cattle to humans occurring through the consumption of 
unpasteurised milk. Consequently, transmission to humans in high income countries, where there is 
near universal pasteurization of milk, has ceased, even when there remains substantial outbreaks in 
cattle populations. Indeed, as a public health intervention it has been estimated to cost close to £4 
million per DALY averted (Torgerson and Torgerson, 2010). Of course it is often stated that there are 
animal health reasons for control, although there are surprisingly little data on the direct costs of bovine
TB to animal health and productivity. The real cost to agriculture is the control programme. Arguably 
the original aims of bovine TB control (i.e. as a public health programme) are being lost with all the 
legal obligations for control and the trade restrictions that could occur in its absence. In the UK, the 
policy of badger culling to prevent transmission has been adopted by Government. This is despite 
evidence of lack of efficacy and poor cost effectiveness (Jenkins et al., 2010). There are better public 
health or indeed animal health deals that could be achieved with the £100 million or more that is being 
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spent by the UK government. Ironically it takes a publication that demonstrates that concurrent 
infection with F. hepatica may reduce the diagnostic efficiency of the bovine tuberculosis test (Claridge
et al., 2012) for bovine fasciolosis, an arguably more important animal disease, to be noticed! In low 
income countries the situation is different. However as it is a food-transmitted disease it is likely that 
introducing controls in the food chain such as milk pasteurization will be of much greater cost 
effectiveness than introducing disease control programmes in cattle such as a test and cull policy. In 
addition, pasteurization of milk will also lower the transmission to humans of other zoonoses such as 
brucellosis. Thus control and elimination programmes are expensive and may have questionable cost 
effectiveness, whilst milk pasteurization as a public health policy is cheap and highly effective.
5. Conclusions
Control of zoonoses is an important part of the “One Health Agenda”. As we live in a world of limited 
resources, control of these disease should be prioritised to those that cause the greatest socio-economic 
impact, providing that the technology is available to tackle these diseases. Cost effectiveness is a useful
tool to prioritise strategies for zoonosis control in terms of cost per DALY averted. This may be in the 
form of regional or national programmes (such as mass treatment of dogs with praziquantel to reduce 
transmission of echinococcosis and hence disease burden in humans) or on an individual basis where 
surveillance and treatment of individual cases may be highly effective, such as with zoonotic human 
trypanosomiosis. The potential benefits to livestock should be considered and cost benefit calculations 
can be made to determine if increased productivity is worth the cost of disease control or elimination. 
In certain diseases the financial benefits of increased animal productivity may more than offset the cost 
of control and, in addition, effectively reduce or eliminate human disease. This essentially makes the 
programme free from the public health perspective. Other diseases, particularly some in high income 
countries attract a lot of resources for control but the societal benefits are marginal and may no longer 
justify such investment. 
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By integrating control of several endemic zoonoses the cost effectiveness may be markedly 
improved. Regular dog treatment with praziquantel combined with control of stray dog populations, 
vaccination against rabies and use of insecticidal collars would be of benefit in controlling 
echinococcosis, rabies and leishmaniosis. These three zoonoses are co endemic over substantial parts of
the world and the marginal cost of vaccinating a dog against rabies and supplying an insecticidal collar 
when they are treated with praziquantel is relatively small as the main costs in such programmes are 
personnel and infrastructure. There are also new tools becoming available. Vaccinating livestock 
against E. granulosus is now a reality (Lightowlers, 2006) and modelling suggests that when combined 
with other measures it may have a strong synergistic effect (Torgerson, 2006). Integrating vaccination 
of sheep against echinococcosis and brucellosis is also likely to be cost effective as both zoonoses are 
often highly endemic in the flocks of nomadic pastoralists. Likewise, vaccination of pigs against 
cysticercosis is likely in the near future (Gauci et al., 2012) and vaccines against Fasciola have shown 
promise (Dalton et al., 2003). To optimise resources for the control of zoonoses, evidence based 
studies, some of which have been summarized in the present article, can be used to optimise the agenda
for disease control and hence ensure disease control programmes are not only effective but are cost 
effective and/or have a positive cost benefit.
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